金石亚药(300434) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥314,985,330.83, a decrease of 16.42% compared to ¥376,878,105.52 in the same period last year[3] - Net profit attributable to shareholders was ¥66,575,529.07, down 15.62% from ¥78,903,060.71 year-on-year[3] - The company reported a basic earnings per share of ¥0.17, a decrease of 15.00% from ¥0.20 in the same period last year[3] - Total operating revenue for the current period is CNY 314,985,330.83, a decrease of 16.4% compared to the previous period's CNY 376,878,105.52[20] - Net profit for the current period is CNY 65,601,623.66, a decrease of 16.5% from CNY 78,609,558.98 in the previous period[21] Cash Flow and Assets - The net cash flow from operating activities increased significantly by 155.25%, reaching ¥15,346,997.87, compared to a negative cash flow of ¥27,776,881.44 in the previous year[3] - Cash and cash equivalents decreased from CNY 235,431,122.99 to CNY 210,215,459.01, a decline of about 10.7%[16] - Total current assets decreased from CNY 946,786,046.66 at the beginning of the year to CNY 821,642,972.78, a reduction of approximately 13.2%[17] - Operating cash flow for the current period is CNY 15,346,997.87, compared to a negative cash flow of CNY -27,776,881.44 in the previous period[25] - Total cash inflow from operating activities is CNY 264,446,558.18, while total cash outflow is CNY 249,099,560.31, resulting in a net cash inflow[25] Equity and Liabilities - Total assets at the end of the reporting period were ¥2,644,934,285.63, down 4.45% from ¥2,768,127,717.25 at the end of the previous year[3] - The company's equity attributable to shareholders increased by 2.18% to ¥2,129,257,386.23 from ¥2,083,751,254.61 at the end of the previous year[3] - Total liabilities decreased from CNY 606,118,784.35 to CNY 455,041,320.47, a reduction of approximately 25%[18] - The company reported a total equity increase from CNY 2,162,008,932.90 to CNY 2,189,892,965.16, an increase of approximately 1.3%[19] Research and Development - The company reported a decrease in research and development expenses to CNY 12,937,760.46 from CNY 21,152,317.65 in the previous period, a reduction of 38.5%[20] - The company received government subsidies amounting to ¥3,035,541.67, primarily related to biopharmaceutical industry research and development[5] Market and Strategic Focus - The decrease in net profit and revenue is attributed to market demand fluctuations and the impact of COVID-19 and industry policies[7] - The company is focusing on enhancing marketing efforts and improving management efficiency while exploring opportunities in traditional Chinese medicine sectors[7] - The company acquired an additional 25% stake in its subsidiary, which contributed to a decrease in minority interests[7] - The company acquired a 25% stake in Zhejiang Di'er Pharmaceutical Co., Ltd. for a transfer price of CNY 35,772,506, increasing its ownership from 52.73% to 77.73%[14] Miscellaneous - The first quarter report of Sichuan Jinshi Asia Pharmaceutical Co., Ltd. is unaudited[26] - The report does not provide specific financial performance metrics or user data for the first quarter[26] - There are no details on future outlook or performance guidance mentioned in the report[26] - The company has not disclosed any new product or technology developments in the first quarter[26] - There is no information regarding market expansion or acquisitions in the report[26] - The report lacks any mention of new strategies implemented during the first quarter[26] - The board of directors has confirmed the absence of an audit for the first quarter report[26] - No specific revenue figures or percentage changes are provided in the report[26] - The report does not include any commentary on competitive positioning or market trends[26] - There are no insights shared regarding operational challenges or achievements in the first quarter[26]